General Information |
Summary |
The purpose of this study is:
To evaluate the safety and tolerability of RPE cellular therapy in patients with SMD Group.
When-MA09-hRPE cell transplantation to evaluate the safety of surgical procedures.
In future studies intended to assess the number of transplanted hRPE cells.
In the past, MA09-hRPE cell therapy used in the study was to evaluate the validity of the potential.
Homologous retinal pigment epithelial cells derived from embryonic stem cells, future studies of drugs that are used in representing the potential validity to evaluate the optimal dose. |
Description |
Not Provided |
Clinical trials phase |
Phase 1 |
Start date (estimated) |
2012-09-01 |
End date (estimated) |
2015-06-30 |
Clinical feature |
Label |
Stargardt disease |
Link |
http://purl.obolibrary.org/obo/DOID_0050817 |
Description |
An age related macular degeneration that is characterized by progressive vision loss usually to the point of legal blindness. |
|
Administrative Information |
NCT number |
NCT01625559 |
ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT01625559 |
Other study identifiers |
|
Source weblink |
https://clinicaltrials.gov/ct2/show/study/NCT01625559 |
Regulatory body approval |
Name |
Korea Food and Drug Administration (KFDA) |
Country |
|
|
Public contact |
Email |
info@chabio.com |
First name |
Wonkyung |
Last name |
Song |
Country |
|
Address freetext |
CHA Bundang Medical Center |
|
Sponsors |
CHABiotech CO., Ltd |
Cells |
Source pluripotent stem cell lines |
|
Which differentiated cell type is used |
Label |
retinal pigment epithelial cell |
Link |
http://purl.obolibrary.org/obo/CL_0002586 |
Description |
An epithelial cell of the retinal pigmented epithelium. |
|
Recruitment |
Recruitment Status |
Unknown Status |
Estimated number of participants |
3 |